By Randy Osborne, Staff Writer
Although Merck & Co. Inc. continues to chalk up investor-pleasing sales with Keytruda (pembrolizumab) and Bristol-Myers Squibb Co. (BMS) keeps doing well with Opdivo (nivolumab), researchers have yet to strike upon the best combinations with other agents.
Program
Indication
Discovery
Preclinical
Phase 1 Safety
Dose-Escalation
Phase 1b
Dose-Expansion/
Efficacy Signal
AB928 (Dual Adenosine Receptor Antagonist) LEARN MORE
AB928+AB122
CRPC, RCC
AB928+AB122+Carbo/Pem
NSCLC
AB928+mFOLFOX
CRC, GEC1
AB928+PLD2
TNBC, Ovarian1
AB928+PLD2+IPI-549
TNBC
AB680 (Small Molecule CD73 Inhibitor) LEARN MORE
AB680+AB122+Gem/nab-paclitaxel
Pancreatic
AB122 (Anti-PD-1 Antibody) LEARN MORE
AB122
Biomarker-selected
(tumor-type agnostic)
AB154 (Anti-TIGIT Antibody) LEARN MORE
AB154+AB122
NSCLC
Discovery and Preclinical Small Molecules
AB610 (PI3Kγ Inhibitor)
Oncology Indications
HIF-2α Antagonist
Oncology Indications
Axl Inhibitor
Oncology Indications
PAK4 Inhibitor
Oncology Indications
Developing Innovative © 2019 Arcus Biosciences. All Rights Reserved. Privacy Policy | Terms of Use | Twitter Terms of Use and Disclaimers